scholarly journals A Logical levothyroxine dose Individualization: Optimization Approach at discharge from Radioiodine therapy ward and during follow-up in patients of Differentiated Thyroid Carcinoma: Balancing the Risk based strategy and the practical issues and challenges: Experience and Views of a large volume referral centre in India

2013 ◽  
Vol 28 (1) ◽  
pp. 1
Author(s):  
Sandip Basu ◽  
Devendra Chaukar ◽  
AnilK DCruz ◽  
Amit Abhyankar ◽  
Ramesh Asopa
Keyword(s):  
Thyroid Carcinoma ◽  
Large Volume ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Optimization Approach ◽  
Referral Centre ◽  
Dose Individualization

scholarly journals Radioiodine concentration by the thymus in differentiated thyroid carcinoma: report of five cases

2009 ◽  
Vol 53 (7) ◽  
pp. 874-879 ◽  
Author(s):  
Maria Eduarda Mello ◽  
Rodrigo C. Flamini ◽  
Rossana Corbo ◽  
Marcelo Mamede
Keyword(s):  
Thyroid Carcinoma ◽  
False Positive ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Whole Body Scan ◽  
Body Scan ◽  
Radioiodine Uptake

The radioactive iodine has been used with great value as a diagnostic and therapeutic method in patients with differentiated thyroid carcinoma previously submitted to total thyroidectomy. False-positive whole-body scans may occur due to misinterpretation of the physiologic distribution of the radioisotope or lack of knowledge on the existence of other pathologies that could eventually present radioiodine uptake. Thymic uptake is an uncommon cause of false-positive whole-body scan, and the mechanism through which it occurs is not completely understood. The present paper reports five cases of patients with differentiated thyroid cancer who presented a mediastinum uptake of radioiodine in a whole-body scan during follow-up. The patients had either histological or radiological confirmation of the presence of residual thymus gland. It is very important to know about the possibility of iodine uptake by the thymus in order to avoid unnecessary treatment, such as surgery or radioiodine therapy.

scholarly journals Outcome of Well-Differentiated Thyroid Carcinoma Patients Receiving a Cumulative Doses of ? 600 mCi (22GBq) of I-131

2016 ◽  
Vol 17 (2) ◽  
pp. 114-119
Author(s):  
Faria Nasreen ◽  
Nurun Nahar ◽  
Sadia Sultana ◽  
Faridul Alam
Keyword(s):  
Bone Metastasis ◽  
Thyroid Carcinoma ◽  
Papillary Carcinoma ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Thyroid Remnant ◽  
Follicular Variant ◽  
Cumulative Activity ◽  
Well Differentiated

Background: There is no maximum limit for cumulative dose of I-131 for persistent disease in well-differentiated thyroid carcinoma (DTC) patients. However, most remissions are obtained with cumulative activity equal to or lower than 600 mCi (22 GBq). On the other hand a significantly increased risk of leukemia and secondary cancers has been reported with high cumulative dose of I-131 (? 600 mCi). Above this cumulative activity further radioiodine therapy should be taken on an individualized basis.Objective: The aim of the study was to see the outcome of patients with well differentiated thyroid carcinoma receiving a cumulative doses (CDs) of ? 600 mCi I-131.Patient and Method: A retrospective study of 72 patients with DTC receiving a CDs of ?600 mCi I-131 in the National Institute of Nuclear Medicine and Allied Sciences (NINMAS), Dhaka during the period of January 1994 up to December 2007 was carried out. Initially all patients were treated by thyroidectomy followed by radioiodine therapy as adjusted by standard protocol. The mean period of follow up was 8.9 ± 6 years.  From the medical files, age, gender, histopathological variant, thyroid remnant and radio ablation doses, follow up data were recorded. Age was further categorized as <45 and ?45 years. Thyroid bed remnant was designated as significant if the thyroid bed uptake was ?5% after surgery. Dose was categorized in ?5 dose and > 5 doses to find its association with status on last follow up. Disease free (DF) was established as: undetectable or suppressed serum Tg levels <2.0 ng/mL and stimulated serum Tg level <10 ng/mL, two consecutive negative whole body scans.Results: A total of 38 patients had papillary carcinoma, eight had follicular variant of papillary carcinoma and 26 had follicular carcinoma. Age range at diagnosis was nine to 72 years. There were 22 males and 50 females giving a M: F ratio of about 1:2. Among the 72 patients 25 patients had lymph node metastases, eight had lung metastases and 20 had bone metastases at presentation. Twenty-one patients died during the whole observation period and 20 of them were cancer related. Two patients developed second malignancy.Conclusion: DTC patients with follicular variant, ? 45 years of age, having bone metastasis and significant thyroid remnant have less favourable outcome in spite of high cumulative doses of radioiodine. DTC patients with higher TNM stage and bone metastasis require higher and more radioiodine doses.Bangladesh J. Nuclear Med. 17(2): 114-119, July 2014

131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

1987 ◽  
Vol 26 (03) ◽  
pp. 139-142 ◽  
Author(s):  
G. Arning ◽  
O. Schober ◽  
H. Hundeshagen ◽  
Ch. Ehrenheim
Keyword(s):  
Serum Level ◽  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Level ◽  
Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

Long-term follow-up of differentiated thyroid carcinoma in children and adolescents

2020 ◽  
Vol 33 (11) ◽  
pp. 1431-1441
Author(s):  
Montserrat Negre Busó ◽  
Amparo García Burillo ◽  
Marc Simó Perdigó ◽  
Pere Galofré Mora ◽  
Maria Boronat de Ferrater ◽  
...  
Keyword(s):  
Complete Remission ◽  
Thyroid Carcinoma ◽  
Children And Adolescents ◽  
Differentiated Thyroid Carcinoma ◽  
Radioiodine Treatment ◽  
Persistent Disease ◽  
Stage 4 ◽  
Long Term Follow Up

AbstractObjectivesThe aims were to analyze the clinical features, response to treatment, prognostic factors and long-term follow-up of children and adolescents with differentiated thyroid carcinoma (DTC).MethodsEighty patients with DTC were studied retrospectively. All underwent total or near-total thyroidectomy, and in 75 cases, ablative iodine therapy was recommended. Patients were assessed periodically by tests for serum thyroglobulin levels and whole-body iodine scans. Age, gender, initial clinical presentation, histology, tumor stage, postoperative complications, radioiodine treatment protocol, treatment response, thyroglobulin (Tg), recurrence and long-term disease progression were evaluated.ResultsSeventy patients completed >2 years of follow-up (23 males, 47 females; median age: 14 years; range: 3–18 years). Sixty-two patients showed papillary DTC and eight, follicular DTC. Sixty-five percent presented nodal metastasis and 16%, pulmonary metastasis at diagnosis. Six months after first radioiodine treatment, 36.2% of patients were free of disease. Seven recurrences were documented. At the end of follow-up, overall survival was 100%, and 87.2% of patients were in complete remission. Nine patients had persistent disease. We found a significant association between stage 4 and persistent disease. Hundred percent of patients with negative Tg values at 6 months posttreatment were documented free of disease at the end of the follow-up. The analysis of disease-free survival based on radioiodine treatment protocols used showed no statistically significant differences.ConclusionsDTC in children and adolescents is frequently associated with presence of advanced disease at diagnosis. Despite this, complete remission was documented after treatment in most cases, with a good prognosis in the long-term follow-up. Negative posttreatment thyroglobulin and stage 4 at diagnosis were significant prognostic variables.

scholarly journals Ultrasound-guided implantation of radioactive 125I seed in radioiodine refractory differentiated thyroid carcinoma

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wei Chen ◽  
Yu kun Luo ◽  
Ying Zhang ◽  
Qing Song ◽  
Jie Tang
Keyword(s):  
Thyroid Carcinoma ◽  
Reduction Rate ◽  
Differentiated Thyroid Carcinoma ◽  
Comprehensive Treatment ◽  
Efficacy And Safety ◽  
Ultrasound Guided ◽  
Contrast Enhanced ◽  
The Us ◽  
Median Volume

Abstract Background Treatment for radioiodine refractory differentiated thyroid carcinoma (RR-DTC) is challenging. The purpose of this study was to assess the efficacy and safety of ultrasound-guided implantation of radioactive 125I-seed in radioiodine refractory differentiated thyroid carcinoma. Methods Thirty-six cervical metastatic lymph nodes (CMLNs) diagnosed with RR-DTC from 18 patients were enrolled in this retrospective study. US and contrast-enhanced ultrasound (CEUS) examinations were performed before implantation. Follow-up comprised US, CEUS, thyroglobulin (Tg) level and routine hematology at 1–3, 6, 9 and 12 months and every 6 months thereafter. The volumes of the nodules were compared before implantation and at each follow-up point. The volume reduction rate (VRR) of nodules was also recorded. Results The median volume of the nodules was 523 mm3 (148, 2010mm3) initially, which decreased significantly to 53mm3 (0, 286mm3) (P < 0.01) at the follow-up point of 24 months with a median VRR as 95% (86,100%). During the follow-up period (the range was 24–50 months), 25 (69%) nodules had VRR greater than 90%, of which 12 (33%) nodules had VVR ≈ 100% with unclear structures and only 125I seed images were visible in the US. At the last follow-up visit, the serum Tg level decreased from 57.0 (8.6, 114.8) ng/ml to 4.9 (0.7, 50.3) ng/ml, (P < 0.01). Conclusion US-guided 125I seed implantation is safety and efficacy in treating RR- DTC. It could be an effective supplement for the comprehensive treatment of thyroid cancer.

scholarly journals Long-Term Follow-Up for Differentiated Thyroid Carcinoma Patients: A Reconsideration

Thyroid ◽  
2017 ◽  
Vol 27 (3) ◽  
pp. 475-476 ◽  
Author(s):  
Robin A.L. van der Wardt ◽  
Adrienne C.M. Persoon ◽  
Esther N. Klein Hesselink ◽  
Thera P. Links
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document